


EARLY STEP-UP PLAN FOR POLYARTICULAR ONSET/COURSE JIA WITHOUT POOR PROGNOSTIC FACTORS

All JIA categories (except systemic) **without** RF, CCP, radiographic damage, or arthritis of hip, cervical, wrist or sacroiliac joints, in combination with moderate/high disease activity¹



JADAS= Juvenile Arthritis Disease Activity Scale

Footnote 1: Moderate/high disease activity defined as ≥ 1 active joint, elevated ESR or CRP, or MD or Pts global ≥ 3 (see ref 2).

Footnote 2: Adalimumab, etanercept (if no uveitis or IBD), golimumab, or infliximab (in line with the Norwegian LIS TNF BIO recommendations).

Footnote 3: If tried 2 anti TNFs, change mechanism to tocilizumab or abatacept.

The treatment plan is based on the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus treatment plans, expert reviews, and the American College of Rheumatology (ACR) treatment plans.

References

1. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, Prahalad S, Schneider R, Shenoi S, Vehe RK, Kimura Y; Juvenile Idiopathic Arthritis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. *Arthritis Care Res (Hoboken)*. 2014 Jul;66(7):1063-72
2. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. *Arthritis Care Res (Hoboken)*. 2011 Apr;63(4):465-82
3. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. Calasan MB¹, Wulffraat NM. *Expert Rev Clin Immunol*. 2014 Jul;10(7):843-54. doi: 10.1586/1744666X.2014.916617.
4. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Rheum* 2009 May 15;61(5):658-66.
5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgerit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. *Ann Rheum Dis*. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715.
6. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. *Ann Rheum Dis*. 2017 Jun;76(6):978-991